27F, 1320-10, Seocho 2-dong, Seocho-gu
60 articles with Samsung Biologics
Samsung Biologics breaks ground on Super Plant, the world's largest and most innovative bio-manufacturing facility
Samsung Biologics officially began construction of its Plant 4 in Incheon, South Korea.
Samsung Biologics announces strategic manufacturing partnership with Lilly to accelerate delivery of COVID-19 antibody treatments
Samsung Biologics' partnership with Eli Lilly and Company is expected to greatly accelerate the global supply for Lilly's COVID-19 antibody therapies through a long-term manufacturing agreement, with the ultimate goal of making antibody treatments more globally accessible for patients.
Samsung Biologics' Virtual Exhibition Hall earns top industry award for digital creativity and innovation
Samsung Biologics' Virtual Exhibition Hall was recently recognized for its highly interactive digital capabilities and virtual reality technology to connect with clients around the world.
The life sciences industry is one of the fastest growing in the world. BioSpace provides a rundown of companies announcing facility and job expansions across the U.S. and beyond.
Samsung Biologics Establishes Partnership with China Biotech GeneQuantum Healthcare to Collaborate on ADC Development
Samsung Biologics has entered into a strategic partnership with GeneQuantum Healthcare, a China biotech company, to jointly develop an antibody drug conjugate for the treatment of non-small-cell lung carcinoma, triple-negative breast cancer, and other solid tumors.
Samsung Biologics Co., Ltd. and Checkpoint Therapeutics, Inc., announced the expansion of a long-term manufacturing partnership for Checkpoint's anti-PD-L1 antibody, cosibelimab.
Samsung Biologics maintained steady financial results for its fiscal 2020 third quarter ending September 30, demonstrating confident execution of its ongoing business operations.
Samsung Biologics has entered into a partnership agreement with biotech Dinona, further expanding its CDO capabilities to provide a full scope of its development services from cell line development, process development, to non-clinical and clinical material manufacturing.
Samsung Biologics has entered into a partnership agreement with BioEleven to develop and manufacture BN-101A, a third-generation immunotherapy to treat cancer.
Samsung Biologics and AstraZeneca announced on Monday that they have entered a long-term supply agreement, expected to be valued at approximately $330 million.
Samsung Biologics signs strategic partnership with Kanaph Therapeutics to develop treatment for retinal diseases
Samsung Biologics (207940.KS) and Kanaph Therapeutics have entered into a strategic partnership to develop KNP-301, a bi-specific Fc fusion protein intended to treat retinal diseases.
Samsung Biologics (207940.KS) and AstraZeneca announced a long-term supply agreement, valued at approximately $330.8 million . Under this agreement, Samsung Biologics will provide large-scale commercial manufacturing for drug substance in its Plant 3 as well as drug product to support AstraZeneca's biologics therapeutic
A London AI Hub, a Facility Bigger than the Louvre, Are Among the Newest Footprint Expansions in ...
9/3/2020GlaxoSmithKline has opened a new $13 million research hub in London focused on artificial intelligence.
Samsung Biologics (KRX: 207940.KS) announced today strong financial results for its fiscal 2020 second quarter ending June 30, 2020 , maintaining steady business performance with a high operating margin at 26.4%. The Company recorded a revenue of KRW 307.7 billion , an increase of 48.5% quarter-on-quarter, and an
Samsung Biologics (207940.KS) announced a plan to expand its Drug Product (DP) capability in line with increasing market demand and to ensure flexible production capabilities for new and existing clients.
Samsung Biologics and ImmuneOncia Therapeutics held a signing ceremony for a contract to develop and manufacture five candidate molecules, expanding upon the two companies' existing CDO partnership first established in 2018.
Samsung Biologics has further expanded its partnership with STCube through an additional development and manufacturing service agreement of STM418, an anti-PD1 immuno-oncology candidate.
Samsung Biologics announced the launch of a Virtual Exhibition Hall, coinciding with the opening of BIO Digital 2020 week.
Samsung Biologics announced it has attained ISO22301 certification for additional business operations, demonstrating its unsurpassed commitment to ensuring client satisfaction and operational excellence through its world-class business continuity management system.
Samsung Biologics and ImmuneOncia Therapeutics Inc. Development and Manufacturing Agreement Accomplishes IND Clearance of IMC-002 (anti-CD47 antibody)
Samsung Biologics and ImmuneOncia Therapeutics Inc. announced the successful FDA IND approval of IMC-002 under a development and manufacturing agreement with Samsung Biologics since 2018.